Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec before radical prostatectomy for prostate cancer
ACTRN12620001286932Phase 2Recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- May 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in prostate cancer (PCa) and prostate adenocarcinoma (3 arms), sponsored by Royal Melbourne Hospital. Primary endpoints: Intratumoral Pexa-Vec CD8-based antitumor response, Intravenous Pexa-Vec CD8-based antitumor response and 1 more. Started May 2023; status: recruiting.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on ACTRN12620001286932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001286932.